久久久久久国产免费a片,五月婷婷一区二区,亚洲日本香蕉视频观看视频

FDA Approves CtexliTM (chenodiol) for the Treatment of Rare Disease Cerebrotendinous Xanthomatosis FDA FDA Drug Approvals Chenodeoxycholic acid FDA approves CtexliTM (chenodiol) for the treatment of Cerebrotendinous Xanthomatosis (CTX), a rare genetic disorder affecting bile acid metabolism. CtexliTM is the first FDA-approved drug for CTX, offering a new treatment option for patients.
FDA Approved Summay - Januaray 2025 FDA Drug Approvals FDA Explore FDA drug approvals from January 2025, including treatments for Crohn's disease, colorectal cancer, Alzheimer's, migraine, and more. Key approvals from Eli Lilly, Amgen, AstraZeneca, and others reshape patient care options.
Continued Anti-Dumping Duties on Imported Ortho-Dichlorobenzene from Japan and India MOFCOM Ortho Dichlorobenzene The Ministry of Commerce announced continued anti-dumping duties on imported ortho-dichlorobenzene from Japan and India starting January 23, 2025, for 5 years, to protect the Chinese industry from potential dumping and damage.
Implementation of the Windsor Framework: UK's Pharmaceutical Regulation Unified Windsor Framework Discover how the Windsor Framework unifies UK pharmaceutical regulations, resolves Northern Ireland supply issues, and introduces new licensing, labeling, and logistics rules for seamless drug distribution post-Brexit.
US Implements New Biotechnology Export Control, May Affect China Import & Export BIS The US is set to impose new export controls on biotechnology equipment, impacting China. The controls focus on advanced tools in biotechnology, addressing national security concerns and the dual-use nature of certain technologies.
FDA 2025 Q1 Approval Overview (II) FDA Drug Approvals FDA Explore the FDA 2025 Q1 approval overview, featuring groundbreaking treatments like Vimseltinib for TGCT, Mirdametinib for NF1-PN, and innovative therapies in oncology, immunology, and more.
FDA 2025 Q1 Approval Overview (I) FDA Drug Approvals FDA The FDA's 2025 Q1 approval pipeline includes promising treatments for diabetes, cancer, and central nervous system disorders. Key candidates include Ozempic for kidney disease, Subvenite for epilepsy, and TX05, a HER2-targeted cancer biosimilar.
FDA Approvals Summary - December 2024 FDA Drug Approvals FDA The FDA approved several major drugs in December 2024, including treatments for Alzheimer's, cystic fibrosis, hemophilia, and cancer. This list highlights key drugs like Zepbound, Alyftrek, and Ensacove, marking significant advances in various therapeutic areas.
Inventory of Regulations, Policies, and Market Trends on Recycled Plastics Plastic Recycling EU Explore global trends in recycled plastics regulations, policies, and market conditions across the EU, US, China, Japan, South Korea, Thailand, and India. Discover key strategies to boost recycling, sustainability, and the circular economy.
2024 FDA Approved Small Molecule Drugs FDA FDA Drug Approvals Small Molecule Discover the FDA-approved small molecule drugs of 2024, covering treatments for rare diseases, cancers, and chronic conditions. From innovative therapies like Iqirvo for primary biliary cholangitis to breakthrough options in neurology and oncology.

< Pre 1 234 5 6 Next >

News Archives

All Categories

Industry News Agricultural News Industrial News Cosmetic News Exhibition News Food News Science News Pharmaceutical News

永久免费毛片_亚洲成人看片_亚洲春色另类_亚洲综合免费视频_最新高清无码专区_午夜影院a

Chemical Policy

HOT Topics